Monthly Archives: October 2009

Positive results for Logical Therapeutics’ LT-NS001 vs. Naproxen clinical study

Logical Therapeutics, Inc. announced positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Endocyte awarded patent for vitamin receptor binding drug delivery conjugates

Endocyte, Inc. has been awarded a patent from the United States Patent and Trademark Office covering vitamin receptor binding anti-cancer agents. The patent, entitled “Vitamin Receptor Binding Drug Delivery Conjugates” (U.S. Patent No. 7,601,332), covers novel conjugation linkages and anti-cancer agents, including Endocyte’s EC145, which is currently in development as a potential treatment for ovarian and non-small cell lung cancers.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Oncolytics® Biotech Inc. issues 33rd U.S. patent

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) has been granted its 33rd U.S. Patent, No. 7,608,257, entitled “Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus.” The patent claims cover methods of using reovirus in combination with currently approved chemotherapeutic agents to treat patients that are refractory to those chemotherapeutic agents alone. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Biotech and the flu pandemic

Biotechnology researchers are working to create new vaccination options to help stop the next big pandemic before it starts.  Join Dr. Targan of BIO’s BioBytes as he walks us through the current steps in vaccine production, and what biotechnology is doing to help create new vaccines in quicker timeframes to help meet the global demand (click link below for video). For those of you attending the 8th Annual BIO Investor Forum this week in San Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

Record soy exports expose critical flaw in land use theory

As has been pointed out multiple times on this blog, there are serious flaws in the theory of indirect land use change (ILUC) and the models used to predict it. But that’s not where the flaws end. There are also significant errors in data. As National Biodiesel Board CEO Joe Jobe said in a recent interview regarding ILUC theory: The elements that are not predictions, that are known, quantifiable data are actually wrong. Well, another piece Read More >

Biofuels & Climate Change  |  46 Comments  |  Email This Post
Tags: , ,